Cytosol vascular endothelial growth factor in endometrial carcinoma

Correlation with disease-free survival

Chi An Chen, Wen Fang Cheng, Chien Nan Lee, Lin Hung Wei, Jan Show Chu, Fon Jou Hsieh, Chang Yao Hsieh

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objective. The aim of this study was to evaluate whether vascular endothelial growth factor (VEGF) could be a marker for disease-free survival in endometrial carcinoma patients. Methods. Fifty-three patients with endometrial carcinoma undergoing surgery were enrolled. Clinical and pathologic items were recorded. Cytosol VEGF was quantified by enzyme immunoassay. The microvessel density (MVD) of the excised tumors was immunohistochemically assessed. The relationship among MVD, cytosol VEGF concentration of the tumor tissues, and clinicopathologic parameters was analyzed. The risk factors influencing clinical outcome were tested. Results. Higher cytosol VEGF concentrations and MVD values were noted in tumors with advanced stage (more than stage I) (917 versus 125 pg/mg, P = 0.03; 94.1 ± 37.8 versus 60.8 ± 38.9, P = 0.008), lymphovascular emboli (917 versus 102 pg/mg, P = 0.001; 94.4 ± 33.2 versus 62.4 ± 40.7, P = 0.009), and lymph node metastasis (1032 versus 95 pg/mg, P <0.001; 116.5 ± 30.8 versus 56.7 ± 33.3, P <0.001). The cytosol VEGF and MVD showed a positive linear correlation (VEGF versus MVD, r = 0.41, P = 0.003). Grade 3 tumor and overexpressed cytosol VEGF (>800 pg/mg) are independent risk factors for recurrence. There was a trend that patients with grade 1 or 2 tumors and normal-expressed VEGF had the highest probability of disease-free survival, and patients with grade 3 tumors and overexpressed cytosol VEGF had the poorest probability of disease-free survival. Conclusions. Cytosol VEGF had a good correlation with the disease progression and metastasis in endometrial carcinoma, and it might also be an independent prognostic factor for disease-free survival of endometrial carcinoma patients.

Original languageEnglish
Pages (from-to)207-212
Number of pages6
JournalGynecologic Oncology
Volume80
Issue number2
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Endometrial Neoplasms
Cytosol
Vascular Endothelial Growth Factor A
Disease-Free Survival
Microvessels
Neoplasms
Neoplasm Metastasis
Embolism
Immunoenzyme Techniques
Disease Progression
Lymph Nodes
Recurrence

Keywords

  • Endometrial carcinoma
  • Microvessel density
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Cytosol vascular endothelial growth factor in endometrial carcinoma : Correlation with disease-free survival. / Chen, Chi An; Cheng, Wen Fang; Lee, Chien Nan; Wei, Lin Hung; Chu, Jan Show; Hsieh, Fon Jou; Hsieh, Chang Yao.

In: Gynecologic Oncology, Vol. 80, No. 2, 2001, p. 207-212.

Research output: Contribution to journalArticle

Chen, Chi An ; Cheng, Wen Fang ; Lee, Chien Nan ; Wei, Lin Hung ; Chu, Jan Show ; Hsieh, Fon Jou ; Hsieh, Chang Yao. / Cytosol vascular endothelial growth factor in endometrial carcinoma : Correlation with disease-free survival. In: Gynecologic Oncology. 2001 ; Vol. 80, No. 2. pp. 207-212.
@article{1d8427aa274c477f9865fa1544d025ab,
title = "Cytosol vascular endothelial growth factor in endometrial carcinoma: Correlation with disease-free survival",
abstract = "Objective. The aim of this study was to evaluate whether vascular endothelial growth factor (VEGF) could be a marker for disease-free survival in endometrial carcinoma patients. Methods. Fifty-three patients with endometrial carcinoma undergoing surgery were enrolled. Clinical and pathologic items were recorded. Cytosol VEGF was quantified by enzyme immunoassay. The microvessel density (MVD) of the excised tumors was immunohistochemically assessed. The relationship among MVD, cytosol VEGF concentration of the tumor tissues, and clinicopathologic parameters was analyzed. The risk factors influencing clinical outcome were tested. Results. Higher cytosol VEGF concentrations and MVD values were noted in tumors with advanced stage (more than stage I) (917 versus 125 pg/mg, P = 0.03; 94.1 ± 37.8 versus 60.8 ± 38.9, P = 0.008), lymphovascular emboli (917 versus 102 pg/mg, P = 0.001; 94.4 ± 33.2 versus 62.4 ± 40.7, P = 0.009), and lymph node metastasis (1032 versus 95 pg/mg, P <0.001; 116.5 ± 30.8 versus 56.7 ± 33.3, P <0.001). The cytosol VEGF and MVD showed a positive linear correlation (VEGF versus MVD, r = 0.41, P = 0.003). Grade 3 tumor and overexpressed cytosol VEGF (>800 pg/mg) are independent risk factors for recurrence. There was a trend that patients with grade 1 or 2 tumors and normal-expressed VEGF had the highest probability of disease-free survival, and patients with grade 3 tumors and overexpressed cytosol VEGF had the poorest probability of disease-free survival. Conclusions. Cytosol VEGF had a good correlation with the disease progression and metastasis in endometrial carcinoma, and it might also be an independent prognostic factor for disease-free survival of endometrial carcinoma patients.",
keywords = "Endometrial carcinoma, Microvessel density, Vascular endothelial growth factor",
author = "Chen, {Chi An} and Cheng, {Wen Fang} and Lee, {Chien Nan} and Wei, {Lin Hung} and Chu, {Jan Show} and Hsieh, {Fon Jou} and Hsieh, {Chang Yao}",
year = "2001",
doi = "10.1006/gyno.2000.6048",
language = "English",
volume = "80",
pages = "207--212",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Cytosol vascular endothelial growth factor in endometrial carcinoma

T2 - Correlation with disease-free survival

AU - Chen, Chi An

AU - Cheng, Wen Fang

AU - Lee, Chien Nan

AU - Wei, Lin Hung

AU - Chu, Jan Show

AU - Hsieh, Fon Jou

AU - Hsieh, Chang Yao

PY - 2001

Y1 - 2001

N2 - Objective. The aim of this study was to evaluate whether vascular endothelial growth factor (VEGF) could be a marker for disease-free survival in endometrial carcinoma patients. Methods. Fifty-three patients with endometrial carcinoma undergoing surgery were enrolled. Clinical and pathologic items were recorded. Cytosol VEGF was quantified by enzyme immunoassay. The microvessel density (MVD) of the excised tumors was immunohistochemically assessed. The relationship among MVD, cytosol VEGF concentration of the tumor tissues, and clinicopathologic parameters was analyzed. The risk factors influencing clinical outcome were tested. Results. Higher cytosol VEGF concentrations and MVD values were noted in tumors with advanced stage (more than stage I) (917 versus 125 pg/mg, P = 0.03; 94.1 ± 37.8 versus 60.8 ± 38.9, P = 0.008), lymphovascular emboli (917 versus 102 pg/mg, P = 0.001; 94.4 ± 33.2 versus 62.4 ± 40.7, P = 0.009), and lymph node metastasis (1032 versus 95 pg/mg, P <0.001; 116.5 ± 30.8 versus 56.7 ± 33.3, P <0.001). The cytosol VEGF and MVD showed a positive linear correlation (VEGF versus MVD, r = 0.41, P = 0.003). Grade 3 tumor and overexpressed cytosol VEGF (>800 pg/mg) are independent risk factors for recurrence. There was a trend that patients with grade 1 or 2 tumors and normal-expressed VEGF had the highest probability of disease-free survival, and patients with grade 3 tumors and overexpressed cytosol VEGF had the poorest probability of disease-free survival. Conclusions. Cytosol VEGF had a good correlation with the disease progression and metastasis in endometrial carcinoma, and it might also be an independent prognostic factor for disease-free survival of endometrial carcinoma patients.

AB - Objective. The aim of this study was to evaluate whether vascular endothelial growth factor (VEGF) could be a marker for disease-free survival in endometrial carcinoma patients. Methods. Fifty-three patients with endometrial carcinoma undergoing surgery were enrolled. Clinical and pathologic items were recorded. Cytosol VEGF was quantified by enzyme immunoassay. The microvessel density (MVD) of the excised tumors was immunohistochemically assessed. The relationship among MVD, cytosol VEGF concentration of the tumor tissues, and clinicopathologic parameters was analyzed. The risk factors influencing clinical outcome were tested. Results. Higher cytosol VEGF concentrations and MVD values were noted in tumors with advanced stage (more than stage I) (917 versus 125 pg/mg, P = 0.03; 94.1 ± 37.8 versus 60.8 ± 38.9, P = 0.008), lymphovascular emboli (917 versus 102 pg/mg, P = 0.001; 94.4 ± 33.2 versus 62.4 ± 40.7, P = 0.009), and lymph node metastasis (1032 versus 95 pg/mg, P <0.001; 116.5 ± 30.8 versus 56.7 ± 33.3, P <0.001). The cytosol VEGF and MVD showed a positive linear correlation (VEGF versus MVD, r = 0.41, P = 0.003). Grade 3 tumor and overexpressed cytosol VEGF (>800 pg/mg) are independent risk factors for recurrence. There was a trend that patients with grade 1 or 2 tumors and normal-expressed VEGF had the highest probability of disease-free survival, and patients with grade 3 tumors and overexpressed cytosol VEGF had the poorest probability of disease-free survival. Conclusions. Cytosol VEGF had a good correlation with the disease progression and metastasis in endometrial carcinoma, and it might also be an independent prognostic factor for disease-free survival of endometrial carcinoma patients.

KW - Endometrial carcinoma

KW - Microvessel density

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0035133926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035133926&partnerID=8YFLogxK

U2 - 10.1006/gyno.2000.6048

DO - 10.1006/gyno.2000.6048

M3 - Article

VL - 80

SP - 207

EP - 212

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -